Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have recently become the standard first-line therapy for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. This study aimed to define the role of EGFR-TKI treatment in the adjuvant setting of patients with resected EGFR-mutant NSCLC. Methods: Three online databases (PubMed, Embase, and the Cochrane Library) were used to conduct systematic research to search for studies published before June 1, 2020. The disease-free survival (DFS) and overall survival (OS) of patients with resected EGFR-mutant NSCLC after radical surgery treated with EGFR-TKIs versus non-EGFR-TKIs in the adjuvant setting were compared. Based on rigorous self-defined inclusion and exclusion criteria, studies were selected, and a meta-analysis was performed using hazard rate (HR) and 95% CIs as effective measures. Results: Eleven studies, published between 2011 and 2020, with a total of 1,900 patients, were included in this meta-analysis. EGFR-TKI treatment showed a significant beneficial effect on DFS (HR 0.42; 95% CI 0.31–0.57) and OS (HR 0.62; 95% CI 0.45–0.86) for patients with resected EGFR-mutant NSCLC after radical resection in the adjuvant setting. Conclusion: Our meta-analysis results suggested that EGFR-TKI treatment improved the DFS and OS of completely resected patients with EGFR-mutant NSCLC compared with non-EGFR-TKI treatment in the adjuvant setting. In the future, our conclusion should be confirmed by additional large-scale and well-designed clinical trials.
Oncol Res Treat

中文翻译：

---

表皮生长因子受体酪氨酸激酶抑制剂在切除表皮生长因子受体突变非小细胞肺癌患者的辅助治疗中的疗效：11 项试验的荟萃分析

背景：表皮生长因子受体酪氨酸激酶抑制剂 (EGFR-TKIs) 最近已成为携带 EGFR 突变的晚期非小细胞肺癌 (NSCLC) 患者的标准一线治疗方法。本研究旨在确定 EGFR-TKI 治疗在切除 EGFR 突变 NSCLC 患者的辅助治疗中的作用。方法：使用三个在线数据库（PubMed、Embase 和 Cochrane Library）进行系统研究，以检索 2020 年 6 月 1 日之前发表的研究。比较了在辅助治疗中用 EGFR-TKI 和非 EGFR-TKI 治疗根治性手术后的突变 NSCLC。根据严格的自定义纳入和排除标准，选择研究，并以危险率（HR）和95% CIs作为有效措施进行荟萃分析。结果：该荟萃分析纳入了 2011 年至 2020 年间发表的 11 项研究，共有 1,900 名患者。EGFR-TKI 治疗对辅助治疗中根治性切除后已切除的 EGFR 突变 NSCLC 患者的 DFS（HR 0.42；95% CI 0.31–0.57）和 OS（HR 0.62；95% CI 0.45–0.86）有显着的有益影响. 结论：我们的荟萃分析结果表明，与辅助治疗中的非 EGFR-TKI 治疗相比，EGFR-TKI 治疗改善了完全切除的 EGFR 突变 NSCLC 患者的 DFS 和 OS。未来，我们的结论应该得到更多的大规模和精心设计的临床试验的证实。
肿瘤资源治疗